drugset / Trial / NCT01641081

Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

NCT01641081

Phase 2 Completed 174 enrolled AstraZeneca
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this Phase II study is to evaluate efficacy and safety of inhaled formoterol fumarate in the Pressair DPI compared to the Foradil Aerolizer in patients with mild to moderate asthma. This study will include a screening visit followed by a 4 month treatment period.

Timeline

Start
2012-06
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Formoterol Other / unclassified 6 ug Inhaled
Subject Formoterol Other / unclassified 12 ug Inhaled
Subject Formoterol Other / unclassified 24 ug Inhaled

Indications